Degron Therapeutics


Degron Therapeutics is developing a new class of small molecule molecular glue degrader (MGD) drugs using their proprietary platform GlueXplorer®. They focus on targeting intractable disease targets with structurally differentiated compounds, advanced screening, and validation systems. Their mission is to develop novel MGDs for historically difficult targets, leveraging proprietary data sets and innovative scaffold chemistry.

Industries

biotechnology
health-care
oncology

Nr. of Employees

medium (51-250)

Degron Therapeutics

Shanghai, Shanghai, China, Asia


Products

HuR-targeting molecular glue degrader clinical candidate (IND cleared)

A first-in-class small-molecule degrader that targets the RNA-binding protein HuR; reported IND clearance by the U.S. FDA to support clinical development in solid tumors.


Services

Collaborative discovery and co-development

Partnerships to co-discover and co-develop molecular glue degrader programs using the company's library, screening systems, and data resources.

Translational and preclinical development support

Translational research and preclinical programme execution to advance optimized small-molecule degraders toward IND-enabling studies.

Expertise Areas

  • Targeted protein degradation
  • Molecular glue degrader discovery
  • Small-molecule medicinal chemistry
  • High-throughput screening and assay development
  • Show More (4)

Key Technologies

  • Molecular glue degrader discovery
  • Compound-induced proximity assays
  • High-throughput screening
  • Ternary complex mechanistic analysis
  • Show More (4)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.